Affiliations 

  • 1 a Eli Lilly SA , Dubai , United Arab Emirates
  • 2 b Hospital Universiti Sains Malaysia , Kelantan , Malaysia
  • 3 c The Chinese University of Hong Kong , Hong Kong , China
  • 4 d St. Luke's Medical Center , Quezon City , Philippines
  • 5 e Eli Lilly and Company , Budapest , Hungary
  • 6 f Eli Lilly and Company (Taiwan) Inc
  • 7 g Eli Lilly and Company , Indianapolis , IN , USA
  • 8 h Division of Endocrinology and Metabolism, Department of Internal Medicine , Taichung Veterans General Hospital , Taichung , Taiwan
  • 9 i Rajavithi Hospital, Rangsit Medical School , Bangkok , Thailand
Curr Med Res Opin, 2018 09;34(9):1653-1662.
PMID: 29863422 DOI: 10.1080/03007995.2018.1484712

Abstract

OBJECTIVE: Current and future estimates of the burden of diabetes for the Western Pacific (WP) region are among the highest in the world. Verifying Insulin Strategy and Initial Health Outcome Analysis (VISION) was an 18 month observational study that explored treatment approaches in patients with type 2 diabetes mellitus (T2DM) initiating insulin in the WP region.

METHODS: A total of 1065 patients aged ≥18 years with T2DM initiating insulin therapy in normal clinical course were enrolled from Hong Kong, Malaysia, Philippines, Taiwan and Thailand. Participants' data was recorded by the treating physicians. Patient-reported outcomes (PROs) were assessed using questionnaires completed by participants.

RESULTS: The mean age of patients was 57.2 years with mean glycosylated hemoglobin (HbA1c) of 10.0%. About 66% of patients had an HbA1c ≥9.0% at insulin initiation despite 74% of them being on two or more oral antidiabetic agents at the time of insulin initiation. Basal insulin was initiated in 72% and premixed insulin in 27% of patients. Changes in insulin therapy was observed in 63% of patients and, by the end of study, 28% achieved HbA1c levels of <7.5%. The proportion of patients completely satisfied with their insulin treatment increased over the study course and the quality of life (QoL) score increased from baseline to the study end.

CONCLUSION: As high HbA1C levels indicate a delayed start of insulin therapy, timely initiation and early intensification of insulin therapy is necessary in the region to achieve adequate glycemic control in time and prevent diabetes complications. Data from PROs suggests that the insulin treatment improves QoL in most patients.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications